Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
- 1 October 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 23 (10), 1861-1867
- https://doi.org/10.1097/01.hjh.0000179510.86265.63
Abstract
Angiotensin II causes hypertension not only by direct constriction of vascular smooth muscle, but also by facilitating the release of noradrenaline from sympathetic terminals and by enhancing vascular noradrenaline sensitivity. AT1 receptor antagonists attenuate all these actions, but display some evidence of substance-related selectivities. The contribution of pre- or postsynaptic impairment of sympathetic transmission to long-term antihypertensive efficacy should be determined for four structurally different, clinically approved AT1 antagonists. Spontaneously hypertensive rats were treated with candesartan, eprosartan, irbesartan, or losartan via osmotic minipumps for 4 weeks at doses yielding identical reductions of blood pressure. Maximum efficacy was obtained with a tripled dose of candesartan. In the pithed rat model, stimulus/response dependencies were determined for vasopressor effectivity of preganglionic electrical stimulation, and of intravenous bolus applications of noradrenaline and angiotensin II. Losartan, irbesartan, eprosartan, and candesartan at doses of 5, 40, 20, and 0.05 mg/kg per day, were equally effective in reducing basal systolic blood pressure (-42 mmHg), and the vasopressor potency of angiotensin II (approximately 10-fold). The efficacies of preganglionic stimulation and exogenous noradrenaline were unaltered, with the exception of irbesartan, which reduced vascular noradrenaline sensitivity. The tripled dose of candesartan further reduced basal and angiotensin II-stimulated blood pressures, and significantly attenuated vascular noradrenaline sensitivity. AT1 antagonists at doses that effectively reduce blood pressure in chronic therapy do not generally suppress peripheral sympathetic function. A potential interaction consists in a reduction of vascular noradrenaline sensitivity, which can be considered as a class effect of AT1 antagonists at high dosage.This publication has 32 references indexed in Scilit:
- Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failureAmerican Heart Journal, 2003
- Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart FailureCirculation, 2002
- Angiotensin II Induces Catecholamine Release by Direct Ganglionic ExcitationHypertension, 2002
- Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed ratJournal of Hypertension, 2002
- Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors.Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 2001
- Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan and captoprilJournal of Hypertension, 2001
- Differentiated Response of the Sympathetic Nervous System to Angiotensin-Converting Enzyme Inhibition in HypertensionHypertension, 2000
- Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors.Hypertension, 1993
- IMPROVEMENT OF CHRONIC CONGESTIVE HEART-FAILURE BY ORAL CAPTOPRILThe Lancet, 1979
- Action of angiotensin on uptake, release and metabolism of 14C-noradrenaline by isolated rabbit heartsEuropean Journal of Pharmacology, 1971